Corbus Pharmaceuticals
CRBP
70 hedge funds and large institutions have $8.04M invested in Corbus Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 13 increasing their positions, 18 reducing their positions, and 14 closing their positions.
103% more call options, than puts
Call options by funds: $118K | Put options by funds: $58K
0.15% less ownership
Funds ownership: 1% → 0.85% (-0.15%)
3% less funds holding
Funds holding: 72 → 70 (-2)
14% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 14
28% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 18
59% less capital invested
Capital invested by funds: $19.7M → $8.04M (-$11.7M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$151K |
| 2 |
Mirae Asset Global Investments
Seoul,
South Korea
|
+$88.3K |
| 3 |
Charles Schwab
San Francisco,
California
|
+$32K |
| 4 |
Goldman Sachs
New York
|
+$30.8K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$30K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EMG
ETF Managers Group
Summit,
New Jersey
|
-$1.37M |
| 2 |
D.E. Shaw & Co
New York
|
-$522K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$275K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$191K |
| 5 |
BlackRock
New York
|
-$61K |
CRBP Hedge Fund Activity: Q2 2022 in Review
70 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Corbus Pharmaceuticals (CRBP) for Q2 2022, worth a combined $8.04M — down 59% from $19.7M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of CRBP and 12 opened new positions — a net loss of 2 holders — while 18 trimmed existing stakes and 13 added.
The largest buyer was Renaissance Technologies, adding an estimated $151K. The largest seller was ETF Managers Group, cutting an estimated $1.37M.
- 70 institutional investors held Corbus Pharmaceuticals (CRBP) as of Q2 2022, down from 72 in Q1 2022.
- Funds reported $8.04M of Corbus Pharmaceuticals stock for Q2 2022, down 59% quarter-over-quarter.
- 12 funds opened new Corbus Pharmaceuticals positions in Q2 2022 and 14 closed out, a net change of -2 holders.
- The largest Corbus Pharmaceuticals buyer in Q2 2022 was Renaissance Technologies, an estimated $151K added.
- The largest Corbus Pharmaceuticals seller in Q2 2022 was ETF Managers Group, an estimated $1.37M sold.
Based on aggregated 13F filings for Q2 2022.